Form 4: Exelixis CSO/EVP Aftab Dana Reports Stock Award and 401(k) Holdings
SEC Form 4 Filing
A Form 4 filing reveals that Aftab Dana, CSO/EVP of Discovery & Translational Research at Exelixis, received a stock award and reports holdings in the company's 401(k) plan.
Summary
- A Form 4 filing was submitted by Aftab Dana, CSO/EVP of Discovery & Translational Research at Exelixis, Inc.
- The filing reports a transaction date of February 23, 2024.
- Dana acquired 63,350 shares of common stock through a stock award.
- The price per share for the acquired stock is $0, indicating it was a grant.
- Following the reported transaction, Dana beneficially owns 542,381 shares of Exelixis common stock.
- Dana also indirectly owns 5,835 shares of common stock through the Exelixis, Inc. 401(k) Plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The stock award is a positive sign, but it's not a major event.
Positives
- The stock award to a key executive could be seen as a positive sign of the company's confidence in its future performance.
Future Outlook
The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2025 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates standard compensation practices at Exelixis.
Comparison to Industry Standards
- Stock awards are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock awards as part of their executive compensation packages.
- The vesting schedule of 1/4th annually is a typical vesting schedule for restricted stock units.
Stakeholder Impact
- The stock award aligns the executive's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 02/22/2024 | Date of the Exelixis, Inc. 401(k) Plan statement. |
| 02/23/2024 | Date of the stock award transaction. |
| 02/27/2024 | Date of signature by Nina Ayer, Attorney in Fact. |
| 05/15/2025 | First vesting date for 1/4th of the restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.